Drugs / V3-P
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03165591 | May 2017 → Feb 2020 | malignant pancreatic neoplasm | Immunitor LLC | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | V3-P | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03165591 ↗ |
| Modality | Vaccine | “oral tableted therapeutic vaccine” NCT03165591 ↗ |
| Route | Oral | “Daily tablet of V3-P given orally for 2 months” NCT03165591 ↗ |